ASF1B enhances the migration and proliferation of prostate cancers via regulating p53-related signaling pathways

doi:10.3877/cma.j.issn.1674-3253.2022.03.016

Abstract

Abstract:

Objective

To study the effect of Anti-Silencing Function 1B Histone Chaperone (ASF1B) on the migration and proliferation of prostate cancer (PCa), and to explore the specific molecular mechanism of ASF1B regulating P53-related signal pathway.

Methods

The survival and prognosis of ASF1B in prostate cancer patients was analyzed according to the data in TCGA database. After the expression of ASF1B was knocked down by small interference RNA (SiRNA), the mobility of cells was compared by Transwell cell migration test, the ability of cell proliferation was compared by CCK8 test and plate cloning test, and the apoptosis rate was compared by apoptosis test. The changes of signal pathways after ASF1B knockout were compared by transcriptome second generation sequencing, and the changes of protein and mRNA levels of P53 related signal pathway molecules were compared by Western-Blot test and Q-PCR test, in order to clarify the effect of ASF1B on the migration and proliferation of prostate cancer cells.

Results

After SiRNA knocked down the expression of ASF1B, the motor ability of DU145 and PC3 cells decreased, and the number of cells passing through the chamber decreased at the same time. After knocking down the expression of ASF1B, the number and size of cell viability and colony formation of DU145 and PC3 cells decreased, and the ability of cell proliferation decreased. After knocking down the expression of ASF1B, the percentage of apoptosis of DU145 and PC3 cells increased. After knocking down the expression of ASF1B, the second generation sequencing results of transcriptional group of PC3 cells showed that the P53 signal pathway was regulated. After knocking down the expression of ASF1B, the expression of p21, IGFBP3 and BBC3 of P53-related pathways in PC3 cells increased, while the expression of Cyclin D, Snail and Slug decreased.

Conclusion

ASF1B regulates the migration and proliferation of prostate cancer cells through P53-related signaling pathways in a P53-independent manner. ASF1B is expected to be a new target for the diagnosis and treatment of prostate cancer.

Key words: Prostate cancer, Anti-Silencing Function 1B Histone Chaperone, P53 signaling pathway, Cell migration, Cell proliferation

Zhen Lei, Zhenghui Guo, Chen Tang, Shengmeng Peng, Yanting Ren, Wanhua Wu, Jie Zhou, Yongming Chen, Lingfeng Li, Hai Huang, Yiming Lai. ASF1B enhances the migration and proliferation of prostate cancers via regulating p53-related signaling pathways[J]. Chinese Journal of Endourology(Electronic Edition), 2022, 16(03): 262-269.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2022.03.016

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2022/V16/I03/262

Figures/Tables 6

References 27

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates [J]. Eur Urol, 2020, 77(1): 38-52.
[3]	HA Chung B, Horie S, Chiong E. The incidence, mortality, and risk factors of prostate cancer in Asian men [J]. Prostate Int, 2019, 7(1): 1-8.
[4]	Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in prostate cancer - 29-year follow-up [J]. N Engl J Med, 2018, 379(24): 2319-2329.
[5]	Wallis CJD, Glaser A, Hu JC, et al. Survival and complications following surgery and radiation for localized prostate cancer: an international collaborative review [J]. Eur Urol, 2018, 73(1): 11-20.
[6]	Corpet A, De Koning L, Toedling J, et al. Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer [J]. EMBO J, 2011, 30(3): 480-493.
[7]	Liu X, Song J, Zhang Y, et al. ASF1B promotes cervical cancer progression through stabilization of CDK9 [J]. Cell Death Dis, 2020, 11(8): 705.
[8]	Ma J, Han W, Lu K. Comprehensive pan-cancer analysis and the regulatory mechanism of asf1b, a gene associated with thyroid cancer prognosis in the tumor micro-environment[J]. Front Oncol, 2021, 11：711756.
[9]	Zhou JQ, Qiu T, Chen ZB, et al. Anti-silencing function 1B histone chaperone promotes cell proliferation and migration via activation of the AKT pathway in clear cell renal cell carcinoma[J]. Biochem Biophys Res Commun, 2019, 511(1): 165-172.
[10]	Carrion A, Ingelmo-torres M, Lozano JJ, et al. Prognostic classifier for predicting biochemical recurrence in localized prostate cancer patients after radical prostatectomy[J]. Urol Oncol, 2021, 39(8): 493 e17-e25.
[11]	Hattori N, Ushijima T. Compendium of aberrant DNA methylation and histone modifications in cancer [J]. Biochem Biophys Res Commun, 2014, 455(1-2): 3-9.
[12]	Gurard-levin ZA, Almouzni G. Histone modifications and a choice of variant: a language that helps the genome express itself [J]. F1000Prime Rep, 2014, 6: 76.
[13]	Segura-bayona S, Stracker TH. The Tousled-like kinases regulate genome and epigenome stability: implications in development and disease [J]. Cell Mol Life Sci, 2019, 76(19): 3827-3841.
[14]	Huang J. Current developments of targeting the p53 signaling pathway for cancer treatment [J]. Pharmacol Ther, 2021, 220: 107720.
[15]	Xiao BD, Zhao YJ, Jia XY, et al. Multifaceted p21 in carcinogenesis, stemness of tumor and tumor therapy [J]. World J Stem Cells, 2020, 12(6): 481-7.
[16]	Taylor WR, Stark GR. Regulation of the G2/M transition by p53 [J]. Oncogene, 2001, 20(15): 1803-1815.
[17]	Li M, Wu W, Deng S, et al. TRAIP modulates the IGFBP3/AKT pathway to enhance the invasion and proliferation of osteosarcoma by promoting KANK1 degradation [J]. Cell Death Dis, 2021, 12(8): 767.
[18]	Park J, Jung MJ, Chung WY. The downregulation of IGFBP3 by TGF-beta signaling in oral cancer contributes to the osteoclast differentiation[J]. Biochem Biophys Res Commun, 2021, 534:381-386.
[19]	Shan Z, Liu Q, Li Y, et al. PUMA decreases the growth of prostate cancer PC-3 cells independent of p53 [J]. Oncol Lett, 2017, 13(3): 1885-1890.
[20]	Dey P, Strom A, Gustafsson JA. Estrogen receptor beta upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer [J]. Oncogene, 2014, 33(33): 4213-4225.
[21]	Wang SP, Wang WL, Chang YL, et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug [J]. Nat Cell Biol, 2009, 11(6): 694-704.
[22]	Zhang J, Lei Y, Gao X, et al. p53 Attenuates the oncogenic Ras-induced epithelial-mesenchymal transition in human mammary epithelial cells [J]. Biochem Biophys Res Commun, 2013, 434(3): 606-613.
[23]	Wang Z, Jiang Y, Guan D, et al. Critical roles of p53 in epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma cells [J]. PLoS One, 2013, 8(9): e72846.
[24]	Boutelle AM, Attardi LD. p53 and tumor suppression: it takes a network [J]. Trends Cell Biol, 2021, 31(4): 298-310.
[25]	Marei HE, Althani A, Afifi N, et al. p53 signaling in cancer progression and therapy [J]. Cancer Cell Int, 2021, 21(1): 703.
[26]	蔡江怡，朱乐乐. 组蛋白伴侣ASF1B在前列腺癌细胞的表达及其对体外细胞活力的影响[J]. 中国病理生理杂志, 2020, 36(9): 1602-1607.
[27]	Han G, Zhang X, Liu P, et al. Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer [J]. Int J Oncol, 2018, 53(5): 2056-2066.

siRNA	序列（5’-3’）
Si-NC	UUCUCCGAACGUGUCACGUTT
Si-ASF1B-1	GUGGAAGAUCAUUUAUGUUTT
Si-ASF1B-2	UGGGCUACUACGUCAACAATT

siRNA	序列（5’-3’）
Si-NC	UUCUCCGAACGUGUCACGUTT
Si-ASF1B-1	GUGGAAGAUCAUUUAUGUUTT
Si-ASF1B-2	UGGGCUACUACGUCAACAATT

Please choose a citation manager

Content to export